Boston Scientific Corp. is putting a lot of faith in its Synergy stent to dominate the US drug-eluting market – a device that was only recently approved by FDA to treat coronary artery disease.
During a conference call with reporters on Oct. 5, Kevin Ballinger, Boston Scientific's senior VP and president of its interventional...